| Aug 14 |
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
|
| Aug 13 |
Entrada Therapeutics GAAP EPS of $1.55, revenue of $94.7M
|
| Aug 13 |
Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates
|
| Aug 13 |
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
|
| Aug 12 |
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
|
| Aug 12 |
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
|
| Aug 9 |
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
|
| Aug 9 |
Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
|
| Aug 9 |
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
|
| Aug 8 |
SpringWorks Q2 Earnings Beat, Ogsiveo Drives Revenues
|
